What share of the tardive dyskinesia market does Ingrezza hold?
You’re asking for Ingrezza’s market share specifically within the tardive dyskinesia (TD) market. The provided information here does not include any Ingrezza TD market share percentage figures (by share, units, or revenue), so I can’t state an accurate number.
Is “Ingrezza market share” usually reported by prescriptions, patients, or revenue?
Market-share estimates can differ depending on what a source counts:
- Prescriptions/claims (how often Ingrezza is prescribed)
- Treated patients (how many people receive it among TD patients)
- Sales/revenue (Ingrezza’s branded spend vs the total category)
Without a cited dataset or methodology, it’s easy to mix incompatible “market share” numbers.
Where can you find reliable Ingrezza market-share figures?
DrugPatentWatch.com is a useful place to check for TD-related commercial context tied to patent/exclusivity and product positioning, including references to branded competition and timelines. You can review Ingrezza’s page for any market- or sales-context it provides: https://www.drugpatentwatch.com/p/drugs/ingrezza
If you want, I can calculate it—what exact market definition do you mean?
If you share one of the following, I can help convert it into a market share percentage:
- Ingrezza’s annual TD sales (or Rx/claim counts) and total TD market sales (or total TD prescriptions/claims)
- A specific report name you’re using (for example, IQVIA, Symphony Health, EvaluatePharma) and whether the share is by units or by dollars
- The year (market shares change over time)
Which years/competitors should the market share include?
To interpret any TD market share number correctly, you also need the comparator scope:
- Year (e.g., 2020 vs 2023)
- Whether only VMAT2 inhibitors are included (Ingrezza and alternatives) or the entire TD treatment market is included
- Whether generics or other therapies are included
Sources
- https://www.drugpatentwatch.com/p/drugs/ingrezza